The endotoxin hypothesis of neurodegeneration.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and preclinical data without new human empirical data or systematic review methodology.
PubMed 31519175 · doi:10.1186/s12974-019-1564-7
What was done
This paper synthesized preclinical, experimental, and observational literature to formulate the "endotoxin hypothesis," which proposes that bacterial lipopolysaccharide (LPS/endotoxin) from peripheral sources (e.g., gut, gums, infections) drives or accelerates neurodegenerative pathology.
What was found
No quantitative effect estimates or sample sizes are reported in the abstract. The narrative overview highlights that blood or brain endotoxin is elevated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and systemic conditions like sepsis; endotoxin induces microglial activation in healthy humans and rodents; and endotoxin promotes the aggregation of amyloid-beta, tau, alpha-synuclein, and TDP-43 in experimental models.
Why it matters
The paper outlines a unifying hypothesis linking peripheral bacterial inflammation and barrier permeability to common protein-misfolding neurodegenerative diseases, proposing endotoxin reduction as a potential therapeutic avenue.
Limits
The abstract explicitly notes that the hypothesis remains unproven. As a narrative review, it lacks systematic search criteria or meta-analytic quantification, relies heavily on high-dose rodent experiments that may not reflect human chronic exposure, and demonstrates mechanistic plausibility rather than clinical causation.
Cited by
- supports Changes in gut bacteria leading to intestinal permeability cause increased systemic inflammation that activates microglial cells.
- supports Lipopolysaccharide (LPS) leaking from the gut challenges immune cells to produce inflammatory cytokines that cross to the brain and stimulate microglial cells to become neurodestructive.